[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"monkeypox-mpox\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:monkeypox-mpox":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,75],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100619300","prospective-follow-up-after-mva-bn-booster-vaccination-100619300",false,"NCT07342829","Prospective Follow-up After MVA-BN Booster Vaccination","Prospective On-site Study for the Immunological Follow-up of Individuals Who Received Booster Vaccination With MVA-BN Against Mpox","POQS-Boosted","Inclusion Criteria:\n\n1. Is scheduled to receive a booster dose of MVA-BN\n2. ≥18 years\n3. Willingness to provide written informed consent\n4. Willingness to follow the study schedule\n\nExclusion Criteria:\n\n1\\. Past or current MPXV infection",true,"ALL","18 Years",{"count":21,"type":22},95,"ESTIMATED","2 Years","OBSERVATIONAL","POQS-Boosted is a prospective observational study during which individuals who received Booster vaccination against mpox with the MVA-BN vaccine will be invited to provide biological samples at multiple times over the course of two years.",[27],"Monkeypox (Mpox)",[29,30,31,32],"mpox","immunology","vaccination","booster","NOT_YET_RECRUITING","2026-01-15",{"date":36,"type":37},"2026-01-20","ACTUAL",{"date":34,"type":22},{"date":40,"type":22},"2028-06-30",{"name":42,"class":43},"Institute of Tropical Medicine, Belgium","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":17,"sex":18,"minAge":23,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":4},"100612445","phase-2-evaluate-the-safety-and-immunogenicity-of-the-mva-sibp-vaccine-in-the-democratic-republic-of-the-congo-100612445","NCT07253675","Evaluate the Safety and Immunogenicity of the MVA-SIBP Vaccine in the Democratic Republic of the Congo","Phase 2 Double-Blind, Randomized, Controlled Study of MVA-SIBP Vaccine for Mpox in Age De-escalation in the Democratic Republic of the Congo","Inclusion Criteria:\n\n* Adults: 18 to 45 years inclusive at the time of informed consent. Adolescents: 12 to 17 years inclusive at the time of consent\u002Fassent. Children: 2 to 11 years inclusive at the time of consent\u002Fassent.\n* Participant is in good general health as determined by medical history, targeted physical examination, and clinical judgment of the investigator.\n* Adults: Able to read and understand the written informed consent, and willing to comply with all study procedures and availability for the entire study duration. Adolescents: Parent(s) or legally acceptable representative(s) able and willing to provide written informed consent; participant able and willing to provide appropriate assent per local regulations and IRB requirements. Children: Parent(s) or legally acceptable representative(s), with the relationship to the child similarly verified and documented on the consent form, and able and willing to provide written informed consent.\n* Willing and able to comply with all study procedures, visit schedule, and follow-up requirements as judged by the investigator.\n* No history of smallpox or mpox vaccination. No history of confirmed or suspected infection with monkeypox, cowpox, or vaccinia virus.\n* Negative serum or urine pregnancy test at screening and prior to each vaccination. Willing to use highly effective contraception from 30 days prior to first vaccination through 60 days after the last dose. Breastfeeding.\n* Resides in the study catchment area and has no plans to relocate for the duration of the study. Has reliable access to a telephone and\u002For other means of contact.\n* Adults must have been born in 1980 or later. Able to provide direct written informed consent.\n* Adolescents: Able to provide written or written assent as appropriate. Children: Parent(s)\u002Fguardian(s) able to provide written informed consent; child able to provide assent if developmentally appropriate.\n\nExclusion Criteria:\n\n* Any prior smallpox or mpox vaccination. History of confirmed or suspected infection with monkeypox, cowpox, or vaccinia virus.\n* Close contact, as defined by WHO.\n* Known or suspected immunocompromised state as specified in the protocol.\n* Acute febrile illness (≥38.0°C) or clinically significant infection within 72 hours prior to vaccination. Any acute illness requiring systemic therapy or hospitalization within 14 days prior to enrollment.\n* History of severe allergy or anaphylaxis to any vaccine or vaccine component. History of severe allergic asthma or asthmatic reactions.\n* Pregnant or breastfeeding at screening or planning to become pregnant during the study period.\n* Participation in another clinical trial with an investigational product or vaccine within 6 months prior to enrollment or planned during the study.\n* Receipt of any live vaccine within 28 days or inactivated vaccine within 14 days prior to enrollment or planned within 28 days after any study vaccination.\n* Any medical disease or condition that, in the opinion of the investigator, would place the participant at unacceptable risk, interfere with study objectives, or compromise protocol compliance.\n* Blood transfusion within three months before inclusion. Significant laboratory test result abnormalities should be added as exclusion criteria. Any condition that, in the opinion of the investigator, would preclude safe participation or successful completion of the study.","45 Years",{"count":54,"type":22},180,"INTERVENTIONAL",[57],"PHASE2","To evaluate the safety and immunogenicity of the MVA-SIBP vaccine using a double-blind, randomized, controlled, age de-escalation design conducted in Kinshasa, Democratic Republic of the Congo (DRC).",[27],[61,62,63,64],"Monkeypox","vaccine","safety","immunogenicity","2025-11-19",{"date":67,"type":37},"2025-11-28",{"date":69,"type":22},"2025-12-31",{"date":71,"type":22},"2027-02-28",{"name":73,"class":74},"Shanghai Institute Of Biological Products","INDUSTRY",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":83,"targetDuration":85,"studyType":24,"phases":4,"briefSummary":86,"conditions":87,"keywords":88,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":101,"locationsCount":102},"100580712","epidemiological-and-pathophysiological-insights-through-a-cross-sectional-survey-epic-100580712","NCT06840860","Epidemiological and Pathophysiological Insights Through a Cross-sectional Survey (EPIC)","Monkeypox Biology, Outcome, Transmission and Epidemiology (MBOTE) Study: Epidemiological and Pathophysiological Insights Through a Cross-sectional Survey (EPIC)","MBOTE-EPIC","Inclusion Criteria:\n\n* Apply to be tested for VMPX at HGR or another test center.\n* Patients of all ages and sexes. However, minors under the age of 12 are excluded from questions on sex life.\n* The patient or his\u002Fher culturally acceptable representative is willing and able to give informed consent for participation in the study.\n\nExclusion Criteria:\n\n* NA",{"count":84,"type":22},1000,"10 Days","This study aims to better understand how mpox is spreading in the DRC, how it affects different groups of people, and how well vaccines protect against it. The study is designed as a cross-sectional survey, meaning researchers will collect and analyze data from patients diagnosed with mpox at a single point in time. It will also use a case-control approach, comparing people who test positive for the virus to those who test negative, to identify risk factors and evaluate the effectiveness of the vaccine.",[27],[61,89,90,91,92,93],"Poxviridae Infections","Democratic Republic of Congo","Infections","Virus Diseases","DNA Virus Infections","RECRUITING","2025-04-29",{"date":97,"type":37},"2025-05-02",{"date":99,"type":37},"2025-03-28",{"date":71,"type":22},{"name":42,"class":43},2]